Key result
Simvastatin down-regulated PI3k/Akt signalling and up-regulated FOXO transcription factors and downstream gene targets implicated in muscle proteolysis and inflammation in an in vivo model.
Why the study?
Statin therapy is associated with myopathic changes through a poorly defined mechanism.
Does simvastatin up-regulate genes associated with proteolysis and impair carbohydrate oxidation in an in vivo model?
Does simvastatin up-regulate genes associated with proteolysis and impair carbohydrate oxidation in an in vivo model?
Simvastatin induces early myopathic changes by down-regulating PI3k/Akt signalling and up-regulating FOXO transcription factors, leading to muscle proteolysis and impaired carbohydrate oxidation before overt myopathy occurs.
Answers are grounded in this paper and cite their sources.
Should not alter statin use in patients; hypothesis-generating for myopathy pathways in vivo.
Statins are used clinically for cholesterol reduction, but statin therapy is associated with myopathic changes through a poorly defined mechanism. We used an in vivo model of statin myopathy to determine whether statins up-regulate genes associated with proteasomal- and lysosomal-mediated proteolysis and whether PDK gene expression is simultaneously up-regulated leading to the impairment of muscle carbohydrate oxidation. Animals were dosed daily with 80 mg kg(-1) day(-1) simvastatin for 4 (n = 6) and 12 days (n = 5), 88 mg kg(-1) day(-1) simvastatin for 12 days (n = 4), or vehicle (0.5% w/v hydroxypropyl-methylcellulose and 0.1% w/v polysorbate 80; Control, n = 6) for 12 days by oral gavage. We found, in biceps femoris muscle, decreased Akt(Ser473), FOXO1(Ser253) and FOXO3a(Ser253) phosphorylation in the cytosol (P < 0.05, P < 0.05, P < 0.001, respectively) and decreased phosphorylation of FOXO1 in the nucleus after 12 days simvastatin when compared to Control (P < 0.05). This was paralleled by a marked increase in the transcription of downstream targets of FOXO, i.e. MAFbx (P < 0.001), MuRF-1 (P < 0.001), cathepsin-L (P < 0.05), PDK2 (P < 0.05) and PDK4 (P < 0.05). These changes were accompanied by increased PPARalpha (P < 0.05), TNFalpha (P < 0.01), IL6 (P < 0.01), Mt1A (P < 0.01) mRNA and increased muscle glycogen (P < 0.05) compared to Control. RhoA activity decreased after 4 days simvastatin (P < 0.05); however, activity was no different from Control after 12 days. Simvastatin down-regulated PI3k/Akt signalling, independently of RhoA, and up-regulated FOXO transcription factors and downstream gene targets known to be implicated in proteasomal- and lysosomal-mediated muscle proteolysis, carbohydrate oxidation, oxidative stress and inflammation in an in vivo model of statin-induced myopathy. These changes occurred in the main before evidence of extensive myopathy or a decline in the muscle protein to DNA ratio.
No takes yet. Share an insight, caveat, or question.
Mallinson et al. (2008) studied Statin myopathy (n=21). Simvastatin vs. Vehicle was evaluated on Akt and FOXO phosphorylation and downstream gene transcription (p=<0.05). Simvastatin down-regulated PI3k/Akt signalling and up-regulated FOXO transcription factors and downstream gene targets implicated in muscle proteolysis and inflammation in an in vivo model.
Synapse has enriched 10 related papers. Consider them for comparative context: